

TO: EZIZ Users

FROM: CDPH

SUBJECT: ACIP votes not to use LAIV, the “nasal spray” flu vaccine, this 2016-2017 flu season

DATE: 7/1/16

Dear EZIZ Users:

Last week the federal Advisory Committee on Immunization Practices (ACIP) voted that live attenuated influenza vaccine (LAIV), also known as the “nasal spray” flu vaccine, should **not** be used during the 2016-2017 flu season. This [recommendation for not using LAIV this season](#) is based on data from recent seasons (2013-2016) showing poor or lower than expected vaccine effectiveness.

As of June 30, 2016 the availability of LAIV this autumn is unknown. However, in light of ACIP’s recommendation, MedImmune’s FluMist® will not be offered as part of the California Vaccines for Children (VFC) Program during the 2016-2017 flu season. We recognize this recommendation has implications for Immunization Programs, school-based immunization efforts and vaccine providers, as most of the vaccine supply for the upcoming flu season has already been pre-booked or pre-ordered.

California’s VFC Program will be working with CDC to replace doses of LAIV with alternatives. Based on manufacturer projections, CDC expects that supply of injectable flu vaccine doses for the 2016-2017 season should be sufficient to accommodate any changes resulting from ACIP’s recommendation. Information on which distributors are still accepting pre-booking orders for flu vaccine products can be found [here](#).

ACIP continues to recommend annual flu vaccination with products other than LAIV for everyone 6 months and older. Vaccination is the single best way to prevent influenza, and resulting complications, including hospitalizations and death. Check out EZIZ’s [Flu and Respiratory Disease Prevention Promotional materials](#) to start planning for the upcoming flu season.